News

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of the EMA's initial response

Vyznova is for the treatment of bullous keratopathy of the cornea, a sight-threatening and debilitating condition affecting the endothelial cells of the cornea.

TEPEZZA is the first and only medicine approved in Japan to treat active TED.

Nicole Eter, MD, discussed the use of a magnification implant being used in patients with geographic atrophy (GA) at from this year's EURETINA congress being held in Barcelona, Spain, which took place September 19-22, 2024.

Presented by the National Center for Children’s Vision and Eye Health at Prevent Blindness, the Bonnie Strickland Champion for Children’s Vision Award recognizes efforts by an individual or group of individuals, to improve public health approaches for children’s vision and eye health.

Challenging surgical videos from the Vit-Buckle Society symposia and data on the impact of home OCT in management of nAMD

According to the company, the center, which officially opens on Thursday, September 26, will serve as a hub for hands-on training and education in lens-based vision correction.

Moon Jeong Lee, MD, shares how volunteering in geriatric care shaped her career path.

“[Gene therapy may] dramatically reduce frequency of treatments.”

The option gives Glaukos exclusive global license agreements on pre-agreed terms, including upfront and milestone payments plus royalties.

The study, funded by the National Institutes of Health, supports no change to surgical technique for trichiasis management.

CVD could impact physicians' ability to identify choroidal melanoma from choroidal nevus.

A look back at the 2024 ASRS conference held in Sweden

Pearls from PULSAR, PHOTON, and working practitioners

Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.

The company made notable hires in its biometrics, clinical operations, and market access departments.

Additional previous surgeries and the duration of the SO tamponade had little or no impact

Additional previous surgeries and the duration of the SO tamponade had little or no impact

Veeral Sheth, MD, MBA, FASRS, FACS, discusses outcomes from the Phase 1 HELIOS trial

How retinal imaging can provide clinicians a deeper understanding of myopia

The CHMP will recommend SB15, biosimilar to aflibercept (Eylea), for marketing authorisation by the European Commission

Yousif Subhi, MD, PhD, discusses his Ophthalmologica Lecture, "Things That Matter: An Evidence-Based Approach to AMD and CSC"

Yousif Subhi, MD, PhD, delivered the Ophthalmologica Lecture, "Things That Matter: An Evidence-Based Approach to AMD and CSC."

We spoke with Andrea Govetto, MD, PhD, winner of the inaugural Ramin Tadayoni Award at EURETINA